{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/7283333",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 7283333,
    "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
    "authors" : [ "Swen J J", "Nijenhuis M", "de Boer A", "Grandia L", "Maitland-van der Zee A H", "Mulder H", "Rongen G A P J M", "van Schaik R H N", "Schalekamp T", "Touw D J", "van der Weide J", "Wilffert B", "Deneer V H M", "Guchelaar H-J" ],
    "crossReferences" : [ {
      "@id" : "https://pharmgkb.org/crossReference/pubMed/21412232",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 769250885,
      "resource" : "PubMed",
      "resourceId" : "21412232",
      "_url" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
      "version" : 0
    }, {
      "@id" : "https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 1449247827,
      "resource" : "DOI",
      "resourceId" : "10.1038/clpt.2011.34",
      "_url" : "http://dx.doi.org/10.1038%2Fclpt.2011.34",
      "version" : 0
    } ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ "Animals", "Aryl Hydrocarbon Hydroxylases", "Cytochrome P-450 CYP2C9", "Drug Administration Schedule", "Drug-Related Side Effects and Adverse Reactions", "Humans", "Pharmaceutical Preparations", "Pharmacogenetics", "Practice Guidelines as Topic" ],
    "month" : 5,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "662-73",
    "pediatric" : false,
    "pgkbPublication" : false,
    "pubDate" : "2011-05-01T00:00:00-07:00",
    "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
    "version" : 2,
    "volume" : "89",
    "year" : 2011
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166104986",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166104986",
    "name" : "Annotation of DPWG Guideline for tolbutamide and CYP2C9",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "descriptiveVideoId" : "",
    "guidelineGenes" : [ ],
    "hasTestingGuidance" : false,
    "history" : [ {
      "id" : 1183704541,
      "date" : "2011-08-10T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1450415077,
      "date" : "2019-05-23T16:44:38.917-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450820679,
      "date" : "2019-10-03T16:30:44.974-07:00",
      "description" : "No changes based on August 2019 guidelines",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450956500,
      "date" : "2020-01-31T14:20:45.063-08:00",
      "description" : "Updated link to 2011 DPWG methods",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450963940,
      "date" : "2020-02-11T08:11:05.625-08:00",
      "description" : "Fixed links to 2018 guideline pdfs.",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451704225,
      "date" : "2022-03-03T16:33:31.045-08:00",
      "description" : "Annotation current with May 2021 DPWG Guideline release",
      "type" : "Note",
      "version" : 0
    }, {
      "id" : 1451732865,
      "date" : "2022-03-28T09:57:44.922-07:00",
      "description" : "Annotation current with February 2022 DPWG guideline release",
      "type" : "Note",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/7283333","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":7283333,"title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}],"objCls":"Literature"}, {"@id":"https://pharmgkb.org/literature/15103288","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450815695,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"}],"objCls":"Literature"}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}],"objCls":"Literature"} ],
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA451718",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA451718",
      "name" : "tolbutamide",
      "version" : 9
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA126",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA126",
      "symbol" : "CYP2C9",
      "name" : "cytochrome P450 family 2 subfamily C member 9",
      "version" : 7876
    } ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1447981982,
      "html" : "<p>There are currently no dosing recommendations for tolbutamide based on <em>CYP2C9</em> genotype.</p>\n",
      "version" : 0
    },
    "summaryVideoId" : "",
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1447981981,
      "html" : "<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for tolbutamide based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. See the <a href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</p>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0001903.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Association for the Advancement of Pharmacy - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tolbutamide based on <em>CYP2C9</em> genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].They concluded that there are no recommendations at this time.</p>\n<table class=\"table\">\n<thead>\n<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>\n</thead>\n<tbody>\n<tr><td>CYP2C9 *1/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>\n<tr><td>CYP2C9 *2/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>\n<tr><td>CYP2C9 *1/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>\n<tr><td>CYP2C9 *2/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>\n<tr><td>CYP2C9 *3/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt; 4.5</td></tr>\n</tbody>\n</table>\n<p>Kinetic effect (S) |</p>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods </a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;moderate&quot; quality.</li>\n<li>S: statistically significant difference.</li>\n</ul>\n",
      "version" : 12
    },
    "userId" : "katrin",
    "version" : 22
  }
}